Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

Vertex Pharmaceuticals (VRTX) reported $2.77 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 11.6%. EPS of $4.38 for the same period compares to ...

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.

These results were accompanied by a 63% achievement or five out of the eight study participants of clinical remission defined as UPCR of less than 0.5 grams per gram, negative hematuria and stable ...

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $503.00. The company’s shares ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have appreciated more than 40% since I shifted my coverage to hold/neutral last year, and I am not surprised since the company executed ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Thermo Fisher Scientific, Inc.-5.36% +21.05% ...

The UK Top 40 is broadcast on BBC Radio 1 and MTV, the Top 100 is published exclusively on OfficialCharts.com. View the biggest songs of 2024 so far.